We conducted a double-blinded, placebo-controlled clinical trial to explore how myo-inositol (MI) influences insulin resistance (IR) among obese individuals with non-alcoholic fatty liver disease (NAFLD). Our study involved 48 participants who were randomly assigned to receive either 4 grams of MI or a placebo daily for eight weeks.
Throughout this period, we measured various parameters such as weight, serum glucose levels, and insulin sensitivity indices before and after the intervention. Notably, we found that MI supplementation led to significant improvements in the expression levels of key genes related to the AMPK/PI3K/AKT signaling pathway, which plays a crucial role in regulating metabolism.
The results indicated noteworthy enhancements in insulin resistance for those who received MI, measured through multiple indices, reinforcing its potential benefits for liver health management. Thus, we observed that supplementing with myo-inositol not only bolstered the expression of important metabolic genes but also helped improve insulin resistance in our participants with NAFLD.
Read More
Myo-Inositol shows promise for NAFLDDoes myo-inositol supplementation influence oxidative stress biomarkers in patients with non-alcoholic fatty liver disease?
Direct evaluation of inositol's effects
We aimed to explore the effects of myo-inositol (MI) supplementation on oxidative stress in obese patients suffering from non-alcoholic fatty liver disease (NAFLD). In our double-blinded, placebo-controlled study, 51 newly diagnosed patients were divided into two groups—one receiving 4 grams of MI daily and the other receiving a placebo—while following dietary recommendations for an 8-week period.
At the end of the trial, we observed that both groups experienced significant reductions in body weight and other obesity measures. Interestingly, those taking MI showed a slightly larger decrease in weight, which was statistically significant. While there was no significant difference in most antioxidant levels between the two groups, we noted that the MI group did see a greater reduction in serum nitric oxide.
Although both groups benefited in some ways—like a decrease in feelings of hunger and desire for unhealthy foods—the MI group specifically showed a more pronounced reduction in the desire to eat fatty foods. Overall, MI supplementation positively influenced weight and certain oxidative stress markers, while also providing potential advantages in managing dietary cravings. However, we did not find significant changes in many of the oxidative stress biomarkers related to liver function, emphasizing that while MI appears beneficial for some aspects, more research is needed to fully understand its effects on liver health.
Read More